Saltar al contenido
Merck

V-006

Valproic acid solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño


Acerca de este artículo

Fórmula empírica (notación de Hill):
C8H16O2
Número CAS:
Peso molecular:
144.21
UNSPSC Code:
41116107
NACRES:
NA.24
EC Number:
200-659-6
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

InChI key

NIJJYAXOARWZEE-UHFFFAOYSA-N

InChI

1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)

SMILES string

CCCC(CCC)C(O)=O

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

Quality Level

Gene Information

human ... ALDH5A1(7915)

General description

A Certified Spiking Solution® suitable for use in LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, prescription monitoring or pharmaceutical research. Valproic acid, sold under trade names including Depakote®, Valparin, or Stavzor®, is an antiepileptic drug and mood stabilizer. The drug is prescribed for treatment of epilepsy, bipolar disorder, migraine headaches, and depression.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Depakote is a registered trademark of Sanofi S.A.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Stavzor is a registered trademark of Noven Therapeutics, LLC

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Clase de almacenamiento

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

P C Ho et al.
The pharmacogenomics journal, 3(6), 335-342 (2003-11-05)
The present study investigated the effect of cytochrome P450 2C9 (CYP2C9) genetic polymorphism on the biotransformation of valproic acid (VPA) to its hepatotoxic metabolite, 4-ene-VPA, and compared that to the formation of the inactive 4-OH-VPA and 5-OH-VPA. cDNA-expressed CYP2C9(*)2 and
Matthew D Sztajnkrycer
Journal of toxicology. Clinical toxicology, 40(6), 789-801 (2002-12-12)
Acute valproic acid intoxication is an increasing problem, accounting for more than 5000 calls to the American Association of Poison Control Centers in 2000. The purpose of this paper is to review the pharmacology and toxicology of valproic acid toxicity.
Emily C Bell et al.
Human psychopharmacology, 20(6), 415-424 (2005-08-18)
Previous functional imaging studies have shown altered brain activity during cognitive task performance in bipolar patients. However, the fact that these patients are often on medication makes it unclear to what extent these changes reflect treatment effects. This study aims
Wolfgang Löscher
CNS drugs, 16(10), 669-694 (2002-09-25)
Since its first marketing as an antiepileptic drug (AED) 35 years ago in France, valproate has become established worldwide as one of the most widely used AEDs in the treatment of both generalised and partial seizures in adults and children.
Jakob Christensen et al.
JAMA, 309(16), 1696-1703 (2013-04-25)
Valproate is used for the treatment of epilepsy and other neuropsychological disorders and may be the only treatment option for women of childbearing potential. However, prenatal exposure to valproate may increase the risk of autism. To determine whether prenatal exposure

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico